Activation of Cyclin-Dependent Kinase 5 Is  a Consequence of Cell Death by Ye, Yixia et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2009, Article ID 805709, 11 pages
doi:10.1155/2009/805709
Research Article
Activation of Cyclin-Dependent Kinase 5 Is
a Consequence of Cell Death
Yixia Ye,1 AntonellaTinari,2 Walter Malorni,3 Richard A. Lockshin,4 andZahraZakeri1
1Department of Biology, Queens College and Graduate Center of the City University of New York, Flushing, NY 11367, USA
2Department of Technology and Health, Higher Institute for Health, 00161 Rome, Italy
3Department of Drug Research and Evaluation, Highest Institute for Health, 00161 Rome, Italy
4Department of Biological Sciences, St. John’s University, Jamaica, NY 11439, USA
Correspondence should be addressed to Zahra Zakeri, zahra zakeri@hotmail.com
Received 28 April 2009; Revised 20 June 2009; Accepted 14 July 2009
Recommended by Mauro Piacentini
Cyclin-dependent kinase 5 (Cdk5) is similar to other Cdks but is activated during cell diﬀerentiation and cell death rather than cell
division. Since activation of Cdk5 has been reported in many situations leading to cell death, we attempted to determine if it was
requiredforanyformofcelldeath.WefoundthatCdk5isactivatedduringapoptoticdeathsandthattheactivationcanbedetected
even when the cells continue to secondary necrosis. This activation can occur in the absence of Bim, calpain, or neutral cathepsins.
The kinase is typically activated by p25, derived from p35 by calpain-mediated cleavage, but inhibition of calpain does not aﬀect
cell death or the activation of Cdk5. Likewise, RNAi-forced suppression of the synthesis of Cdk5 does not aﬀect the incidence
or kinetics of cell death. We conclude that Cdk5 is activated as a consequence of metabolic changes that are common to many
forms of cell death. Thus its activation suggests processes during cell death that will be interesting or important to understand, but
activation of Cdk5 is not necessary for cells to die.
Copyright © 2009 Yixia Ye et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Cyclin dependent kinase 5 (Cdk5) is a unique member of
the family of cyclin-dependent kinases, as its activity does
not correlate with cell cycle progression [1]. It is activated
in many instances of neuronal and other cell diﬀerentiation
and, curiously, quite often in cell death. Thus activated Cdk5
is presumed to function in cell death. We therefore decided
to explore the importance of Cdk5 to cell death.
Cdk5, homologous to the prototypic Cdk, human Cdc2,
is also known as neuronal Cdc-2-like kinase (Nclk) [2, 3].
Cdk5 activity is required for neurite migration [4], axon
patterning [5], cortical lamination [6], neuronal secretion
[7], neuronal adhesion [8], diﬀerentiation of oligodendro-
cytes [9], formation of synaptic structure and plasticity, the
maintenance of neuronal cytoarchitecture [10], and perhaps
other functions in the brain. Cdk5 kinase is active in many
other cell types, where it may be involved in diﬀerentiation
[9], exocytosis [11], gene expression [12], cell migration
[13], tissue regeneration, and wound healing and cell death
[14, 15].
Cdk5 is activated in neuronal cell death, such as cell
deathinducedbyremovalofNGFindiﬀerentiatedPC12cells
[16], cell death in the dorsal root ganglia and the trigeminal
ganglia [17], and neuronal cell death in neurological diseases
[3, 18]. Active Cdk5 kinase is also seen in nonneuronal
cell death [19–22]. Cdk5 protein and kinase activity are
elevated in embryonic tissues during normal developmental
cell death in almost all organs manifesting cell death as well
as when death is induced by cyclophosphamide (CP) or
retinoic acid [20, 23, 24]. This activation has been seen in
several cell lines during cell death induced by various toxins
[25, 26]. Cdk5 kinase is likewise activated in several diseases,
such as Alzheimer’s, Huntington’s, Parkinson’s diseases,
Amyotrophic Lateral Sclerosis, and stroke [3, 18, 27, 28].
The consistent activation of Cdk5 in all types of cell death
suggests a fundamental role for this enzyme in activation
or progression of cell death. However there is no direct
demonstration of a function for Cdk5 in cell death. Here we
present evidence that Cdk5 is dispensable for cell death, and
that its activation appears to be a response to, rather than a
controlling mechanism of, cell death.2 Journal of Biomedicine and Biotechnology
We previously showed that Cdk5 may be activated in the
absence of caspase-3, caspase-9, Apaf-1, or p53 [25]. Here
we further demonstrate that Cdk5 activation is independent
of Bim (a Bcl-2 family member in mitochondria), and
cathepsins, such as cathepsin B, D, or L (the most abundant
lysosomal proteases) during cell death.
As with other Cdks, monomeric Cdk5 is enzymatically
inactive; it is activated by association with its speciﬁc
activators. In diﬀerentiating neurons, p35 and p39 are two
major activators [29, 30]. However, other activators such
as cyclin E [31]a n dR I N G O[ 32] can also regulate Cdk5
activity. TNFα can modulate Cdk5 directly without aﬀecting
its activator [33]. More commonly, Cdk5 is activated by p25,
which is generated by the calpain-mediated cleavage of p35
to p25 [25–27]. Although this interpretation is consistently
reported, here we demonstrate that Cdk5 can be activated
in the absence of p25 or p29 (the calpain cleavage products
of p35 and p39) and that cell death is not aﬀected by
the inhibition of calpain. We conclude that Cdk5 may be
activated by means other than interaction with p25 and p29.
Finally,sincedownregulationofCdk5expressionandactivity
does not materially aﬀect cell death, its activity appears to be
a product, rather than a cause, of cell death.
2.MaterialsandMethods
2.1. Antibodies and Reagents. The calpain inhibitor,
PD150606 (Cat# 513022), were obtained from CalBiochem
(La Jolla, CA). Cyclophosphamide (CP Cat#C0768) and
Camptothecin (CPT Cat# C9911) was obtained from Sigma
(St. Louis, MO). The rabbit polyclonal IgG antibodies used
include anti-Cdk5 (C-8, Cat# sc-173) from Santa Cruz
Biotechnology (Santa Cruz, CA), anti-p35 (C-19, Cat#
P9489), and anti-LC3-II (Cat# L7543) antibodies from
Sigma (St. Louis, MO), and anti-phosphohistone H1 (Cat#
06-597) antibody from Upstate Biotechnology (Lake Placid,
NY). The mouse monoclonal antibody used is antiactive
caspase-3 antibody (Cat# 559565) from BD PharMingen
(San Diego, CA).
2.2. Cell Culture and Treatment. (1) C8 cells:C 8i sam o u s e
embryonic ﬁbroblast (MEF) cell line transformed with E1A
and ras (gift from Dr. Scott Lowe, Cold Spring Harbor
Laboratory). Cells were maintained in DMEM (Dulbecco’s
Modiﬁed Eagle Medium, Life Technologies, Rockville, MD)
supplemented with 10% fetal bovine serum, 50U/mL peni-
cillin and 100μg/mL streptomycin, at 37
◦C in a humidiﬁed
atmosphere of 7.5% CO2. At 80% conﬂuence, cells were
exposed in DMEM containing 1% FBS to 50μMc a m p -
tothecin (CPT, dissolved in DMSO) or other cytotoxins, for
8hours or 18hours, times determined to represent modest
and high levels of cell death. To block calpain activation
induced by CPT, 15μM of the synthetic calpain inhibitor
PD150606 was coadministered with CPT, and cells were
incubated for 8hours or 18hours.
(2) COS-7 cells. COS-7 cells were obtained from the
American Type Culture Collection (ATCC) and cultured as
above. At 80% conﬂuence, cells were exposed in DMEM
containing 1% FBS to siRNA of Cdk5 to block Cdk5
expressionandCPT50μMwasco-administeredfor48hours
t oi n d u c ec e l ld e a t h .
(3) Cathepsin-B −/− ,- D−/− ,- L−/− and Wild
Type mouse embryo ﬁbroblast cells. Mouse embryo ﬁbroblast
(MEF) cells obtained from transgenic mouse embryos with
single knockout genotypes of cathepsin-B, -D, or -L or
wild type (WT) were immortalized with SV40 (Gift from
Dr. Marianne Boes, Harvard Medical School). Cells were
cultured in DMEM (Dulbecco’s Modiﬁed Eagle Medium,
Gibco BRL Life Technologies, cat# 12800-017) as above. At
80% conﬂuence, cells were treated in DMEM containing
1% FBS with diﬀerent cytotoxic reagents, such as 50 μM
camptothecin (CPT, dissolved in DMSO), and cells were
collected at 8, 24, and 72hours.
2.3. Injection of CP into Pregnant Mice and Collection of
Embryos. Bim heterozygous mice (gift from Dr. Phillippe
Bouillet, the Walter and Eliza Hall Institute of Medical
Research) were mated overnight, and pregnant female mice
were injected intraperitoneally with 10mg/kg body weight
of CP dissolved in 0.9% saline at gestation day 12.5. The
embryos were removed 18hours after exposure to CP, and
sections were prepared as described below [20].
2.4. Tissue, Slide Preparation, and Microscopy. Pregnant
female mice that had been injected with CP at gestation day
12.5 were sacriﬁced by cervical dislocation one day later, and
the embryos were removed. Embryos were washed with 1X
PBS (Phosphate-Buﬀered Saline, 137mM NaCl, 2.68 mM
KCl, 4.3mM Na2HPO4,1 . 4 m MK H 2PO4, pH 7.4), and
the tail was taken for genotyping. Embryos were washed
with PBS, ﬁxed in 4% paraformaldehyde with shaking at
4◦C for 18–24 hours, and partially dehydrated in 20%
sucrose solution in PBS for 2 days. Embryos were then
embedded in OCT compound (Miles, Elkhart, IN) and
frozen in isopropanol/liquid N2. Special care was used in the
orientation of the mouse embryo or limb samples during
the embedding procedure to make sure the cutting section
represented a good map of the tissue. Frozen sections (5μm)
were cut at −20◦C and placed on VECTABOND-coated
slides and stored at −80
◦Cp r i o rt ou s e .
2.5. Immunohistochemistry. In situ proteins were detected
using the ABC (Avidin-Biotinylated-peroxidase Complex)
kit (Vectastain ABC kit, Vector Laboratory, Burlingame,
CA). Sections were quenched with 0.3% hydrogen peroxide
in methanol at RT for 20minutes to abolish endogenous
peroxidase activity. After three washes with PBST (0.1%
Tween 20 in PBS), sections were incubated in blocking
solution at RT for 1hour and treated with primary antibody
(antibodies against Cdk5 and p35: 0.2 μg/mL; active caspase
3: 0.5μg/mL) at 4◦C in a humidiﬁed chamber overnight.
Following three washes with PBST, secondary biotinylated
antibody was applied to the sections for 1hour at RT.
Sections were then washed with PBST 3x and incubated with
ABC reagent for 2hours at RT. Sections were washed withJournal of Biomedicine and Biotechnology 3
PBST 3x before being visualized with DAB, counterstained
with methylene blue, and mounted with Permount.
2.6. Western Blot. Cells or tissues were lysed in RIPA buﬀer
(50mM Tris, pH 7.5, 150mM NaCl, 1% Triton 100X,
0.1% SDS, 0.5% sodium deoxycholate, 2mM EDTA, and
protease inhibitor cocktail tablets (Boehringer Mannheim,
Germany)), and cell/tissue debris was removed by cen-
trifugation at 13000rpm for 30minutes at 4◦C. Protein
concentration was determined using the Bio-Rad microassay
(Bio-Rad laboratories, Hercules, CA). Equal amounts of
protein were run on 8%, 12.5% or 15% SDS-polyacrylamide
gelsafteraddition ofanequalvolumeof2XLaemmliloading
buﬀer (100mM Tris, pH 7.5, 4% SDS, 20% glycerol, 0.002%
bromophenol blue) [34]. After protein transfer, nitrocellu-
lose membrane blots were blocked with 5% nonfat dry milk
inPBSTfor30minutesandincubatedwithdiﬀerentprimary
antibodies on the shaker overnight at 4◦C. After three washes
with PBST, blots were incubated with horseradish peroxi-
dase (HRP) conjugated goat antirabbit antibody (Jackson
Immuno Research Laboratory, West Grove, PA) for 1 hour
at RT followed by 3 washes. The immune complexes were
detected by chemiluminescence (ECL Plus kit, Amersham,
Chicago, IL) and exposed to autoradiographic ﬁlm.
2.7. In Vitro Histone H1 Kinase Assays. Equal amounts of
lysates from diﬀerent cell samples were incubated with
1.5μg/mL Cdk5 antibody for 1hour at 4◦C , and then
puriﬁed by the addition of protein A-Sepharose (Boehringer
Mannheim, Germany). The precipitated beads were equi-
librated in kinase buﬀer (50mM Tris, pH7.5, 10 mM
MgCl2,1mMDTT,20mMEGTA,0.1mMsodiumvanadate,
80mMβ-glycerophosphate)andcollectedbycentrifugation.
Histone H1 kinase assays were performed in kinase buﬀer
supplemented with 200mM ATP, 50μg/mL calf thymus
histone H1 (Boehringer Mannheim, Germany), and 5μM
cAMP-dependent protein kinase inhibitor (Sigma, St. Louis,
MO) at 30
◦C for 30minutes. An equal volume of 2X
Laemmli buﬀer was added to each sample before they
were denatured at 100
◦C for 2minutes. The phosphorylated
histone H1 was detected by western blot described as above,
using anti-phosphohistone H1 primary antibody.
2.8. Detection of Cell Death by Trypan Blue. The loss of
membrane integrity exhibited in dead and dying cells allows
the preferential uptake of vital dye trypan blue. At the
end of the treatment, cells were pelleted and washed with
PBS. 100 μL of well-suspended cells was mixed with 100 μL
of 0.4% trypan blue solution (in PBS) and left at room
temperature (RT) for 5minutes. Cells were then viewed
under a light microscope and blue stained cells were judged
non-viable.
2.9. Measurement of Nuclear Condensation by Bis-Benzimide.
The DNA ﬂuorochrome bis-benzimide (Hoechst 33258,
Sigma, St. Louis, MO) was used to stain fragmented nuclei
of apoptotic cells. Brieﬂy, cells were trypsinized, pelleted
and washed once with ice cold PBS. The cells were then
resuspended and ﬁxed in 3% paraformaldehyde solution (in
PBS) for 30minutes, washed with ice cold PBS, and incu-
bated with 16μg/mL bis-benzimide in PBS for 25minutes
at RT. Finally, the cells were washed with ice cold PBS once
and resuspended in PBS. 20μL of the cell suspension was
evenly distributed on a slide and covered with a coverslip to
be viewed using an Eclipse TE300 microscope (Nikon Inc.,
Melville, NY).
2.10. RNA Interference. The target sequences were designed
by the siRNA target ﬁnder in http://www.ambion.com/
techlib/misc/siRNA ﬁnder.html. Five 21nt target sequences
were selected randomly. siRNAs were prepared by using
Silence siRNA Construction Kit (Ambion Cat# 1620).
The concentration of siRNA was determined by reading
absorbance at 260nm. siRNAs were transfected into mam-
malian cells, such as COS-7 cells by using siPORT Amine
transfection Agent (Ambion Cat# 4502). Western blotting as
described was used to assay the eﬃciency.
2.11. Electron Microscopy. Cells treated with diﬀerent death
inducers were preﬁxed in 2.5% glutaraldehyde in 0.2M
cacodylate buﬀer, pH 7.2, for 30minutes, and then washed
in cacodylate buﬀer twice. Cells were gently scraped oﬀ
with a rubber policeman and centrifuged in Eppendorf
tubes at 1200g for 5minutes. The postﬁxation was with
1% osmium tetroxide for 2hours at room temperature,
after which the cells were washed with cacodylate buﬀer 3x
and dehydrated through ascending ethanol concentrations
(50%–100%) twice each for 5minutes. The samples were
sent to Dr. Walter Malorni at Higher Institute for Health,
Italy,forfurtherprocessing.SampleswereembeddedinEpon
812, and thin sections were cut, after which the sections
were stained with uranyl acetate and sodium citrate and
observed with Zeiss EM10 electron microscope at 8000X
magniﬁcation.
3. Results
3.1. Cdk5 Activation Is Independent of Bim and Cathepsins.
Sun et al. showed that inhibition of Cdk5 activity can rescue
mitochondrial damage following administration of neuronal
toxins [35], suggesting a role for Cdk5 in the mitochondrial
pathway of apoptosis. To examine this possibility we looked
at the role of Bim in activating Cdk5. Bim, a member
of the BH3-only pro-apoptotic Bcl-2 family, induces the
release of cytochrome c from mitochondria during cell
death through binding with Bax and Bak (the members of
pro-apoptotic Bcl-2 family) to induce their oligomerization
and activation; alternatively, they engage the antiapoptotic
proteins to prevent them from countering Bax and Bak
activation. To examine the eﬀect of Bim on Cdk5 activation,
we used bim transgenic mouse embryos that were exposed
to cyclophosphamide (CP), which can induce massive cell
death during development [20]. Thus these knockouts
can help us to understand the relationship between Cdk5
and mitochondria during cell death. First, we used anti-
Cdk5antibodyandimmunohistochemistrytoexamineCdk54 Journal of Biomedicine and Biotechnology
activity in bim +/+a n db i m−/− mouse embryos after
exposing the mothers to CP as is described in Materials and
Methods. The antibody detects active kinase [17, 24].
We found Cdk5-positive cells in bim +/+ untreated con-
trol and CP-treated embryos and also in bim −/− untreated
control and CP-treated mouse embryos (Figure 1(a)(A)).
The amount of Cdk5 activation was analyzed by t-test by
comparing the number of cells showing Cdk5 activation
from 3 to 5 ﬁelds in diﬀe r e n ts e c t i o n sa th i g hm a g n i ﬁ c a t i o n
(400X ). Cdk5 activity is signiﬁcantly increased in both CP-
treated bim +/+ mouse embryos and CP-treated bim −/−
mouse embryos (Figure 1(a)(B)), indicating that CP can
induce Cdk5 activation during cell death whether or not Bim
is activated. Cdk5 activation appears to be independent of
Bim. Furthermore, we performed TUNEL to examine cell
death induced by CP in both bim −/− and caspase-3 −/−
mouse embryos and found that CP-induced cell death is not
at all dependent on Bim, in contrast to the case for caspase-
3, where we ﬁnd a downregulation of CP-induced cell death
(data not shown).
An alternative common pathway to death involves sub-
stantial autophagy. We therefore examined the interaction
of lysosomes and Cdk5 activity during cell death. For
these experiments we used mouse embryonic ﬁbroblast cells
from transgenic mouse embryos with single knockouts of
cathepsin B, D, or L to determine whether or not these
cathepsins controlled Cdk5 activity. All cells were treated
for 24 hours or 72 hours with camptothecin (CPT), which
inhibits DNA topoisomerase I and thus DNA replication
[36]. First, the amount of cell death was determined by
trypan blue exclusion. (We also performed TUNEL, Hoechst
staining and EM. These data, which were consistent, will be
presented in another paper since this paper is focused on the
relationship of Cdk5 activity and cell death rather than the
mode of death.) These cells were somewhat sensitive to low
serum (1% FBS), so that untreated control WT or cathepsin
B, D, or L −/− cells suﬀered 4%–8% death by 24hours and
5%–12%after72hours.InWTcells,after24hoursexposure,
CPT induced 27% death by 24 hours and 99% by 72 hours;
the corresponding numbers for cathepsin B, D, and L −/−
cells were 7%, 11%, and 8% cell death induced by CPT at 24
hours and 41, 39, and 47% at 72 hours (Figure 1(b)(A)). The
absence of at least one cathepsin modestly protects cells or
at least delays their death, but cathepsins B, D, and L are not
necessary for cell death induced by CPT.
We had previously determined that Cdk5 is a stable
protein and that the level of Cdk5 protein does not change
during induced cell death [20, 23, 25]. Here as well we found
similar levels of Cdk5 expression in both untreated control
and CPT treated cells in both wild type and cathepsin null
cells (Figure 1(b)(B)). The expression of Cdk5 protein was
not aﬀected by either cell death or lack of cathepsins. We
therefore evaluated activation of Cdk5 by the production of
p25 and kinase assay.
First we determined cleavage of the 35kDa protein to
25kDa. Wild type and cathepsin B, D, or L −/− cells were
exposed to CPT for 72 hours, at which time massive cell
death was induced. Equal amounts of protein were extracted
as in Materials and Methods, separated on a 12.5% SDS-
PAGE gel, and subjected to western blot. CPT caused the
generation of a band at 25 kDa (Figure 1(b)(C)). Thus lack
of cathepsin B, D, or L did not aﬀect the generation of p25
during cell death. Next we examined the activity of Cdk5
by its ability to phosphorylate histone H1. Cdk5 kinase was
activated in CPT-treated wild type cells and CPT-treated
cathepsinB,D,orL −/−cellsafter72hoursexposureofCPT,
as determined by detection of the band of phosphorylated
histone H1 at 31kDa (Figure 1(b)(D)). By these several
criteria, activation of Cdk5 kinase is not aﬀected by the
absence of any of these cathepsins. We conclude that Bim
and cathepsin B, D, or L are not required to activate Cdk5
during cell death. The forms of cell death vary according
to the knockouts and cannot readily be assigned to the
classical triumvirate of “apoptosis, autophagy, necrosis.” We
will discuss this issue elsewhere in more expanded form and
address here as aggregate cell death measured by trypan blue.
Since activation of Cdk5 did not depend on any of
these factors, we asked the inverse question, whether Cdk5
activation inﬂuenced the sensitivity of cells to death or the
type of death that they underwent. We therefore examined
the impact of downregulation of Cdk5 activity on cell death.
3.2. Blocking Generation of P25 Does Not Protect Cells from
Death or Prevent Activation of Cdk5 during Cell Death. As
mentioned above Cdk5 is activated by the truncated protein
p25duringcelldeath.Hereweaskedifpreventinggeneration
of p25 would aﬀect Cdk5 activity and cell death. We exposed
C8 cells, which are primary mouse embryonic ﬁbroblast
cells transformed with E1A and ras, to camptothecin (CPT)
and measured cell death by trypan blue dye exclusion. To
assess the involvement of p25 in the activation of Cdk5 and
the induction of cell death, we used the calpain inhibitor
PD150606. This calpain inhibitor inhibits generation of p25
in C8 cells [25]. We conﬁrmed, using western blot and
antibodies detecting both p35 and p25, that p25 formation
was blocked [25]. As shown in Figure 2(a), the untreated
control and PD-treated cells alone showed 7.6% and 7.7%
background cell death respectively after 8, and 15.0% and
15.7% after 18 hours. Although C8 cells are somewhat
sensitive to low serum concentration (1% FBS during
treatment), PD is not toxic. 50 μM CPT killed 43.0% of C8
cells within 8hours and 90.2% by 18 hours (Figure 2(a)).
Addition of 15 μM calpain inhibitor PD simultaneously with
CPT did not alter these ﬁgures; 44.4% of cells were dead
by 8hours and 90.6% by 18hours (Figure 2(a)). We also
looked for nuclear condensation and nuclear fragmentation
by Hoechst staining. Nuclear fragmentation was seen in cells
treated with CPT for 18 hours in the presence or absence of
PD and the number of fragmented nuclei correlated with the
number of dead cells detected by trypan blue exclusion (data
notshown).Thus,preventingtheproductionofp25doesnot
aﬀect the toxicity of CPT or the type of cell killing.
We then asked whether inhibiting generation of p25
aﬀected the expression and activation of Cdk5. Cell lysates
were run on 12% SDS-PAGE and analyzed by western blot
using anti-Cdk5 antibody, as shown in Figure 2(b)(A). A
similar amount of Cdk5 protein is found in both untreatedJournal of Biomedicine and Biotechnology 5
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Figure 1: Cdk5 activation is independent of Bim and cathepsins. (a) Pregnant female mice were injected intraperitoneally as described in
Section 2 . Cdk5 activation by immunohistochemistry showed many cells with Cdk5 activation labeled by Cdk5 antibody in bim +/+a n d
bim −/− mouse embryos with or without CP treatment, 400X. (A) Positive signals were counted in 3–5 ﬁelds of 400X, and the number
of positive signals per ﬁeld was used for plot and analyzed by t-test. (B) The error bars represent the standard deviation from at least three
individual experiments (∗P<. 05 ). (b) Wild type and cathepsin B, D, and L −/− cells were incubated with CPT (50 μM). (A) At 24 and
72hours, the amount of cell death was determined by trypan blue exclusion. The error bars represent standard deviation obtained from at
least 3 independent experiments. Protein samples were isolated from cells with RIPA buﬀer. (B) Western blot analysis of equal amounts of
cell lysates from cells using Cdk5 antibody showed an unchanged level of Cdk5 protein (32kDa) during cell death. (C): Equal amounts of
cell lysates from wild type and cathepsin B, D, and L −/− cells incubated with CPT (50 μM) for 72hours were used for western blot using
p35 antibody. These cells demonstrated an induction of p25 during CPT-induced cell death in the absence of the cathepsins. (D) Histone
H1 kinase activity induced during cell death was detected in Cdk5 immunoprecipitates in wild type cells: cathepsin B −/− cells, cathepsin
D −/− cells, and cathepsin L −/− cells following 72hours treatment with CPT. The histone H1 phosphorylated by Cdk5, as detected by
western blot, increased corresponding to cell death in controls and knockouts. Cdk5 is a relatively stable protein in cells and the expression
of Cdk5 by western can be used as a loading control [20, 25]. Scale mark equals 100μM.6 Journal of Biomedicine and Biotechnology
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Figure 2: Inhibition of calpain does not protect ﬁbroblast C8 cells
fromCPT-inducedcelldeathoractivationofCdk5.(a)C8cellswere
exposed to 50μM CPT in the presence or absence of 15μM calpain
inhibitor, PD, for 8hours or 18hours. The amount of cell death
was measured by trypan blue exclusion. The error bars represent
the standard deviation from at least three individual experiments.
CPTkilled ∼40% of the cells within 8 hours and ∼90% by 18hours,
but PD did not aﬀect the toxicity. (b) Cells treated with 50μM
CPT or CPT plus 15μM PD were collected and lysed by RIPA
buﬀer. (A) Western blot of Cdk5 in equal amounts of cell lysates
from cells treated with CPT or CPT + PD for 18hours showed an
unchanged level of Cdk5 protein (32kDa) during cell death. ((B)
and (C)) Histone H1 kinase activity of Cdk5 immunoprecipitates
was measured using histone H1 as substrate. The histone H1
phosphorylatedbyCdk5wasdetectedbywesternblot(31kDa).The
kinase activity reﬂected the amount of cell death induced, following
8-hour (B) or 18-hour (C) treatment with CPT in the presence
or absence of PD. PD did not aﬀect the amount of histone kinase
activity seen at 8hours, though by 18hours more was lost in the
presence of PD than in its absence.
control and treated cells in the presence or absence of PD.
Cdk5 activity was not detected in untreated or PD-treated
control C8 cells at either 8 or 18hours. In contrast, after
8hours of exposure to CPT, Cdk5 kinase was activated in
CPT-treated cells even when the generation of p25 was
blocked by calpain inhibitor PD (Figure 2(b)(B)). After 18
hours, Cdk5 remained activated in cells exposed to CPT
a l o n eb u tw a sn ol o n g e rd e t e ct e da sa ct i v a t e di nc e l l se x p o s e d
to both CPT and PD (Figure 2(b)(C)). The loss of activated
Cdk5 may result from the fact that by 18hours most of the
cells have died and they are at the last stages of necrosis as
shown below.
These data suggest that the amount of cell death and
level of Cdk5 activation are not aﬀected by inhibiting the
generation of p25, and therefore molecules other than p25
may activate Cdk5 during cell death.
3.3. The Type of Cell Death Is Not Altered by Inhibiting the
Production of P25. We also considered the possibility that
Cdk5 inﬂuences the manner or type of cell death. Since
caspase-3 activation is a hallmark for apoptotic cell death,
we measured caspase-3 activation by western blot using
antiactive caspase-3 antibody. Caspase-3 was activated to
a similar extent in C8 cells exposed to CPT for 8hours
and 18hours whether or not calpain inhibitor was present
(Figure 3(a)(A)). These cells are also capable of fragmenting
their nuclei (data not shown). We examined morphological
changes during induced cell death both with and without
generation of p25. As compared to the untreated normal
control cells and PD-treated cells (Figures 3(b)(A) and
3(b)(B)), CPT-treated cells in both the presence and absence
of PD at 8hours treatment (Figures 3(b)(C) and 3(b)(D))
displayedcondensedandmarginatedchromatinindicativeof
apoptosis. The cytoplasm was vacuolated (potentially dilated
ER cisternae) in some of the cells, indicative of cells with
substantial osmotic problems. At 18hours the CPT-treated
cells in the presence or absence of PD were undergoing
secondary necrosis, as indicated by the disintegration of
the outer plasma membrane and organelles and diﬀuse
appearance of the chromatin which nevertheless can still be
identiﬁed as deriving from apoptosis (Figures 3(b)(E) and
3(b)(F)), indicating the advanced stage of CPT-induced cell
death.
Since we found some vacuolization (Figures 3(b)(C) and
3(b)(D), and data not shown) in the dying cells although
they did not have a typical morphology of autophagosomes,
we examined the activity of one marker of autophagy—that
of cleavage of LC3-I to LC3-II in our cells after 8hours
and 18hours of treatment. β-tubulin was used a loading
control (Figure 3(a)(C)). We found no diﬀerence in the
level of generation of LC3-II in any of the cells examined
(Figure 3(a)(B)).
3.4. Cells Are Not Protected from Death by Downregulation of
Cdk5. p25 is considered to be the most important but not
exclusive activator of Cdk5. Since cell death is not aﬀected by
the lack of p25, we asked how cell death would be impacted
if Cdk5 were downregulated by RNAi. We introduced into
cells ﬁve diﬀerent dsRNAs designed by Ambion (described in
Materials and Methods). In COS-7 cells, some dsRNAs can
decrease the expression of Cdk5 as determined by western
blot (Figure 4(a)). One of the dsRNAs (Cdk5-1, Figure 4(a))
lowered the expression of Cdk5 proteins by 84%. The
dsRNA of Cdk5-3 inhibited Cdk5 expression 60% but Cdk5-
2 dsRNA did not block expression of Cdk5 (Figure 4(a)).Journal of Biomedicine and Biotechnology 7
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Figure 3: Inhibiting production of p25 does not alter the mode of cell death induced by CPT. (a) Western blot of equal amounts of protein
samples from C8 cells treated with CPT or CPT + PD. (A) Cells exposed for 8hours or 18hours showed the activation of caspase-3 (17kDa)
by CPT both in the presence and in the absence of PD. (B): The expression of LC3-II, a 16kDa fragment indicating autophagy, did not
change during the course of death in either control or experimental situations. (C) expression of β-tubulin demonstrated equivalent loading
of protein samples. In summary, CPT marginally increases the activation of caspase 3 with or without PD but does not aﬀect the appearance
of LC3-II. (b) C8 cells treated with CPT or CPT + PD for 8 or 18hours were ﬁxed for electron microscopy. Untreated control C8 cells (A)
and PD treated cells (B) were elongated and displayed large normal nuclei. Cells exposed to CPT in the absence ((C), (E)) or presence ((D),
(F)) of PD showed features of apoptosis ((C) and (D)) after 8hours as well as vacuolization and secondary necrosis after 18hours ((E) and
(F)).
These three dsRNAs (Cdk5-1, Cdk5-2, and Cdk5-3) were
used as control (Cdk5-2) and experimental dsRNA in COS-
7 cells. Percentage of cell death was determined by trypan
blue exclusion. As shown in Figure 4(b),i nc o n t r o lC O S - 7
cells, 25 μM CPT can induce 61.2% cell death by 48hours in
nontransfected cells, compared to 56.7%, 60.8%, and 61.2%
of cell death in Cdk5-1-, Cdk5-2-, and Cdk5-3-transfected
cells, respectively. No signiﬁcant diﬀerence of cell death8 Journal of Biomedicine and Biotechnology
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Figure 4: Inhibition of Cdk5 expression does not protect cells from death. (a) COS-7 cells transfected with dsRNA (Cdk5-1, Cdk5-2, Cdk5-
3) were collected and lysed by RIPA buﬀer. Western blot of equal amounts of cell lysates from COS-7 cells showed Cdk5 expression in all
cells (A), and the amount of Cdk5 was measured by densitometry (B). dsRNA of Cdk5-1 and Cdk5-3 downregulated Cdk5 expression.
(b) COS-7 cells transfected with Cdk5-1, 5-2, or 5-3 dsRNA were treated with 25 μM CPT for 48hours, and cell death was measured by
trypan blue exclusion. Downregulation of Cdk5 by RNAi did not aﬀect the amount of cell death. The amount of cell death was calculated by
subtracting the amount of cell death in untreated control cells. The error bars represent the standard deviation from at least three individual
experiments. (c) COS-7 cells treated with 25μM CPT for 48hours were ﬁxed with 4% paraformaldehyde and stained with Hoechst 33 258
dye. Apoptotic cells manifest condensed and fragmented nuclei as is seen in (D), (E), and (F). (A) Control cells; (D) CPT-exposed control
cells; (B) cells transfected with Cdk5-1; (E) cells transfected with Cdk5-1 and treated with CPT; (C) cells transfected with Cdk5-2; (F) cells
transfected with Cdk5-2 and treated with CPT. The numbers and percent of dead cells were not calculated but appeared to be consistent with
the results presented in Figure 4(b). (d) COS-7 cells were incubated with 25μM CPT for 48hours with or without a dsRNA. After 48hours
incubation, cells were collected and proteins were extracted. Western blots of cell lysates from cells showed the activation caspase-3 by CPT
both in the control cells and transfected cells.Journal of Biomedicine and Biotechnology 9
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Figure 5: Inhibition of Cdk5 expression does not protect cells from death. COS-7 cells treated with CPT at 48hours with or without
transfection of Cdk5 dsRNA were ﬁxed for electron microscopy. (a) and (b) Untreated cells transfected with Cdk5-1 (a) or Cdk5-2 (b)
are elongated and display large nuclei, comparable to controls that were not transfected (see Figure 3(b)(A); otherwise not illustrated). (c)
and (d) CPT-exposed dying cells in control (c) and transfected with Cdk5-1 dsRNA (d) were apoptotic. An apoptotic cell has a condensed
nucleus and cytoplasm and increased electron density while the chromatin is coalesced and electron-dense. Cells killed by CPT are apoptotic
regardless of the concentration of Cdk5.
in transfected cells was seen compared to nontransfected
cells exposed to CPT 48 hours. Thus, downregulation of
expression of Cdk5 to any level by RNAi did not aﬀect the
level of cell death induced by CPT.
3.5. The Mode of Cell Death Is Not Altered by Downregulation
of Cdk5. It remained possible that Cdk5 would aﬀect the
mode of cell death. We exposed cells transfected with
Cdk5-1 and Cdk5-2 to 25 μM CPT for 48hours and
ﬁxed them for Hoechst staining. As shown in Figure 4(c),
nuclear fragmentation was detected in all conditions after
induction of cell death, indicating that the downregulation
of expression of Cdk5 does not aﬀect apoptosis, as indicated
by nuclear fragmentation, during cell death induced by CPT.
In a further test, activation of caspase-3 during cell death
induced by CPT clearly correlated with the induction of
cell death with CPT at 48hours (Figure 4(d)). Thus, CPT
induces caspase-3 activation during cell death irrespective of
downregulation of Cdk5 expression by RNAi.
Finally, we used electron microscopy to evaluate mor-
phological changes during cell death. Apoptotic cells dis-
play cell rounding and chromatin condensation as well as
chromatin margination. Cdk5-1- and Cdk5-2-transfected
but otherwise untreated cells were elongated cells with
normal morphology (Figures 5(a) and 5(b)), indicating that
transfection of Cdk5 did not by itself aﬀect the morphology
of cells. After exposure to CPT for 48 hours, cells that had
not been transfected but were exposed to CPT had apoptotic
morphology such as condensed and fragmented chromatin
and rounding and shrinkage (Figure 5(c)) as did the Cdk5-
1t r a n s f e c t e dc e l l s( Figure 5(d)). Thus the downregulation of
Cdk5 did not aﬀect the type of cell death. Inhibition of Cdk5
expression did not alter the morphological changes during
cell death. The mode of cell death with downregulation of
Cdk5 is also apoptotic.
4. Discussion
Cdk5 was activated in bim −/− mouse embryos during cell
death induced by CP, indicating that the activation of Cdk5
does not require activity of Bim. Our previous data have
shown that the activation of Cdk5 also is independent of the
activity of caspase-3 [25]. This independence might suggest
that Cdk5 activation is upstream of caspase-3 and Bim
activation in the cell death signaling transductions, which
is consistent with claims that action of Cdk5 is upstream of
caspase-3 activation [19] and Cdk5 is an upstream regulator
of mitochondrial dysfunction [34], that Cdk5 is involved in
cell death signaling pathways parallel to the caspase cascade,
and that Cdk5 is activated because cells die but that Cdk5
plays no functional role in the death. Cdk5 is activated and
p25 is generated during cell death in cathepsin B, D, or L
null cells, indicating that Cdk5 activation during cell death
doesnotrequireactivationbycathepsinB,D,orL.Inhibition10 Journal of Biomedicine and Biotechnology
of generation of p25 by calpain likewise conﬁrms that Cdk5
can be activated without p25. The consistent level of Cdk5
protein expression in wild type cells and cathepsin B, or D,
or L −/− cells either untreated or treated with CPT, conﬁrms
our previous but less documented argument [20, 25] that
Cdk5 is a relatively stable protein and that Cdk5 activity is
regulated not at either transcriptional or translational level,
but at a posttranslational level. Since Cdk5 activity is not
aﬀected by knockout of lysosomal proteases, activation of
Cdk5 during cell death cannot be placed downstream of
lysosomal proteases.
Clearly, Cdk5 plays an important role in the diﬀerentia-
tion of neurons [4–10, 27, 28], and perhaps in diﬀerentiating
muscle. However, in other cells and in mature muscle it
seems to be activated during cell death and perhaps only
during cell death. The mechanism and biological purpose of
its activation is unknown.
The calpain inhibitor PD does not reduce the amount of
cell death in either untreated control or CPT-treated cells.
Inhibiting generation of p25 and p29 [25]d o e sn o tp r e v e n t
the generation of the hallmarks of CPT-provoked apoptotic
cell death, caspase-3 activation, and nuclear condensation.
Thus, even when generation of Cdk5 activator p25 and p29
is blocked, cells die through the same signaling pathways.
Cdk5canstillbeactivatedwhenCdk5/p25andCdk5/p29
activity is inhibited, and many proteins have been suggested
as potential activators of Cdk5, but none have been associ-
ated with cell death. Recently, RINGO, a Xenopus protein,
was shown to activate Cdk5 in Xenopus oocytes [32, 37].
p35, which is involved in cell diﬀerentiation, is less stable
than p25, a known activator, and is degraded faster than
p25 but Cdk5/p35 activity also correlates with cell death. For
example,enhancementofCdk5andp35immunoreactivityis
observed in the apoptotic cell body following ischemia [38],
and elevated Cdk5 and p35 activity have been detected in
dying oocytes [17]. Thus, it is possible that p35 by itself can
activate Cdk5.
Inhibition of Cdk5 expression or Cdk5 activation does
not aﬀect the amount of cell death induced by CPT. Neurons
from Cdk5 knockout mice are known to undergo apoptosis,
indicating the existence of Cdk5-independent cell death
pathways [39]. The inactivation of Cdk5 in cells exposed to
CPT and PD for 18hours may reﬂect the shorter half-life
of p35 or, alternatively, inactivation or loss of the enzyme
from these necrotic cells. Our results are consistent with the
interpretation that the presence of activated Cdk5 does not
aﬀect the number of spontaneous or induced deaths.
Although Cdk5 is routinely activated during cell death,
cells can die without Cdk5 activity and the type of cell
death is not altered by inhibition of Cdk5 activity. Thus
Cdk5 activation appears to result from changes during cell
deathratherthancausingorotherwiseinﬂuencingcelldeath.
Nevertheless, the consistent activation of Cdk5 during many
or most types of cell death [40] indicates that the metabolic
changes that activate Cdk5 must be of substantial interest,
potentially revealing mechanisms or vulnerabilities common
to most forms of cell death. We must still determine what
these changes are.
Acknowledgments
This work was supported by funding from NIH and PSC
CUNY Grants to Dr. Zahra Zakeri. The authors also thank
Drs. Marianne Boes and Scott Lowe for providing them with
the cells and Drs. Yong Zhu and Lin Lin for technical advice.
References
[1] L.-H. Tsai, T. Takahashi, V. S. Caviness Jr., and E. Harlow,
“Activity and expression pattern of cyclin-dependent kinase 5
in the embryonic mouse nervous system,” Development, vol.
119, no. 4, pp. 1029–1040, 1993.
[2] J. Lew, R. J. Winkfein, H. K. Paudel, and J. H. Wang, “Brain
proline-directed protein kinase is a neuroﬁlament kinase
which displays high sequence homology to p34cdc2,” The
Journal of Biological Chemistry, vol. 267, no. 36, pp. 25922–
25926, 1992.
[3] F. A.Dhariwala and M. S. Rajadhyaksha, “An unusual member
oftheCdkfamily:Cdk5,”CellularandMolecularNeurobiology,
vol. 28, no. 3, pp. 351–369, 2008.
[4] Y. Hirota, T. Ohshima, N. Kaneko, et al., “Cyclin-dependent
kinase 5 is required for control of neuroblast migration in the
postnatal subventricular zone,” Journal of Neuroscience, vol.
27, no. 47, pp. 12829–12838, 2007.
[5] L. Connell-Crowley, M. Le Gall, D. J. Vo, and E. Giniger, “The
cyclin-dependent kinase Cdk5 controls multiple aspects of
axon patterning in vivo,” Current Biology, vol. 10, no. 10, pp.
599–602, 2000.
[6] S. Raki´ c, C. Davis, Z. Moln´ a r ,M .N i k o l i´ c ,a n dJ .G .P a r n a v e l a s ,
“Role of p35/Cdk5 in preplate splitting in the developing
cerebral cortex,” Cerebral Cortex, vol. 16, supplement 1, pp.
i35–i45, 2006.
[ 7 ]J .L .R o s a l e s ,J .D .E r n s t ,J .H a l l o w s ,a n dK . - Y .L e e ,“ G T P -
dependent secretion from neutrophils is regulated by Cdk5,”
The Journal of Biological Chemistry, vol. 279, no. 52, pp.
53932–53936, 2004.
[8] R. Homayouni and T. Curran, “Cortical development: Cdk5
gets into sticky situations,” Current Biology, vol. 10, no. 9, pp.
R331–R334, 2000.
[9] Y. Miyamoto, J. Yamauchi, J. R. Chan, et al., “Cdk5 regulates
diﬀerentiation of oligodendrocyte precursor cells through the
direct phosphorylation of paxillin,” Journal of Cell Science, vol.
120, no. 24, pp. 4355–4366, 2007.
[10] A. H. Hawasli and J. A. Bibb, “Alternative roles for Cdk5 in
learning and synaptic plasticity,” Biotechnology Journal, vol. 2,
no. 8, pp. 941–948, 2007.
[11] X. Xin, F. Ferraro, N. B¨ ack, B. A. Eipper, and R. E. Mains,
“Cdk5 and Trio modulate endocrine cell exocytosis,” Journal
of Cell Science, vol. 117, no. 20, pp. 4739–4748, 2004.
[12] E.-A. Choe, L. Liao, J.-Y. Zhou, et al., “Neuronal morphogen-
esis is regulated by the interplay between cyclin-dependent
kinase 5 and the ubiquitin ligase mind bomb 1,” Journal of
Neuroscience, vol. 27, no. 35, pp. 9503–9512, 2007.
[13] Y. Feng and C. A. Walsh, “Protein-protein interactions,
cytoskeletal regulation and neuronal migration,” Nature
Reviews Neuroscience, vol. 2, no. 6, pp. 408–416, 2001.
[14] J.C.CruzandL.-H.Tsai,“Cdk5deregulationinthepathogen-
esis of Alzheimer’s disease,” Trends in Molecular Medicine, vol.
10, no. 9, pp. 452–458, 2004.
[15] Q. Guo, “When good Cdk5 turns bad,” Science of Aging
Knowledge Environment, vol. 2006, no. 5, article pe5, 2006.
[16] J.ZhangandG.V.W.Johnson,“Tau protein ishyperphospho-
rylated in a site-speciﬁc manner in apoptotic neuronal PC12Journal of Biomedicine and Biotechnology 11
cells,” Journal of Neurochemistry, vol. 75, no. 6, pp. 2346–2357,
2000.
[17] Q. Zhang, H. S. Ahuja, Z. Zakeri, and D. J. Wolgemuth,
“Cyclin-dependent kinase 5 is associated with apoptotic cell
death during development and tissue remodeling,” Develop-
mental Biology, vol. 183, no. 2, pp. 222–233, 1997.
[ 1 8 ]Z .H .C h e u n g ,A .K .Y .F u ,a n dN .Y .I p ,“ S y n a p t i cr o l e s
of Cdk5: implications in higher cognitive functions and
neurodegenerative diseases,” Neuron, vol. 50, no. 1, pp. 13–18,
2006.
[19] T. Sandal, C. Stapnes, H. Kleivdal, L. Hedin, and S. O.
Døskeland, “A novel, extraneuronal role for cyclin-dependent
protein kinase 5 (CDK5): modulation of cAMP-induced
apoptosis in rat leukemia cells,” The Journal of Biological
Chemistry, vol. 277, no. 23, pp. 20783–20793, 2002.
[20] Y. Zhu, L. Lin, S. Kim, D. Quaglino, R. A. Lockshin, and
Z. Zakeri, “Cyclin dependent kinase 5 and its interacting
proteins in cell death induced in vivo by cyclophosphamide
indeveloping mouseembryos,” Cell Death and Diﬀerentiation,
vol. 9, no. 4, pp. 421–430, 2002.
[21] J. L. Rosales and K.-Y. Lee, “Extraneuronal roles of cyclin-
dependent kinase 5,” BioEssays, vol. 28, no. 10, pp. 1023–1034,
2006.
[ 2 2 ]A .K .U p a d h y a y ,A .K .A j a y ,S .S i n g h ,a n dM .K .B h a t ,“ C e l l
cycle regulatory protein 5 (cdk5) is a novel downstream target
of ERK in carboplatin induced death of breast cancer cells,”
Current Cancer Drug Targets, vol. 8, no. 8, pp. 741–752, 2008.
[23] H. S. Ahuja, W. James, and Z. Zakeri, “Rescue of the limb
deformity in hammertoe mutant mice by retinoic acid-
induced cell death,” Developmental Dynamics, vol. 208, no. 4,
pp. 466–481, 1997.
[24] F. Gao, U. J¨ utting, K. Rodenacker, P. Gais, and P.-Z. Lin, “Rel-
evance of chromatin features in the progression of esophageal
epithelial severe dysplasia,” Analytical Cellular Pathology, vol.
13, no. 1, pp. 17–28, 1997.
[25] L. Lin, Y. Ye, and Z. Zakeri, “P53, Apaf-1, caspase-3, and -9 are
dispensable for Cdk5 activation during cell death,” Cell Death
and Diﬀerentiation, vol. 13, no. 1, pp. 141–150, 2006.
[26] L. Cagnon and O. Braissant, “Role of caspases, calpain and
cdk5 in ammonia-induced cell death in developing brain
cells,” Neurobiology of Disease, vol. 32, no. 2, pp. 281–292,
2008.
[27] M. Slevin and J. Krupinski, “Cyclin-dependent kinase-5
targeting for ischaemic stroke,” Current Opinion in Pharma-
cology, vol. 9, no. 2, pp. 119–124, 2009.
[28] P. Paoletti, I. Vila, M. Rif´ e, J. M. Lizcano, J. Alberch,
and S. Gin´ es, “Dopaminergic and glutamatergic signaling
crosstalk in Huntington’s disease neurodegeneration: the role
ofp25/cyclin-dependentkinase5,”JournalofNeuroscience,vol.
28, no. 40, pp. 10090–10101, 2008.
[ 2 9 ]L . - H .T e a i ,I .D e l a l l e ,V .S .C a v n e s sJ r . ,T .C h a e ,a n dE .
Harlow, “p35 is a neural-speciﬁc regulatory subunit of cyclin-
dependent kinase 5,” Nature, vol. 371, no. 6496, pp. 419–423,
1994.
[30] D. Tang, J. Yeung, K.-Y. Lee, et al., “An isoform of the neuronal
cyclin-dependent kinase 5 (Cdk5) activator,” The Journal of
Biological Chemistry, vol. 270, no. 45, pp. 26897–26903, 1995.
[31] R. Donnellan and R. Chetty, “Cyclin E in human cancers,” The
FASEB Journal, vol. 13, no. 8, pp. 773–780, 1999.
[32] A. Dinarina, L. H. Perez, A. Davila, M. Schwab, T. Hunt, and
A. R. Nebreda, “Characterization of a new family of cyclin-
dependentkinaseactivators,”BiochemicalJournal,vol.386,no.
2, pp. 349–355, 2005.
[33] D. I. Orellana, R. A. Quintanilla, and R. B. Maccioni, “Neuro-
protective eﬀect of TNFα against the β-amyloid neurotoxicity
mediated by CDK5 kinase,” Biochimica et Biophysica Acta, vol.
1773, no. 2, pp. 254–263, 2007.
[34] U. K. Laemmli, “Cleavage of structural proteins during the
assembly of the head of bacteriophage T4,” Nature, vol. 227,
no. 5259, pp. 680–685, 1970.
[35] K.-H. Sun, Y. de Pablo, F. Vincent, and K. Shah, “Deregulated
Cdk5 promotes oxidative stress and mitochondrial dysfunc-
tion,” Journal of Neurochemistry, vol. 107, no. 1, pp. 265–278,
2008.
[36] E. J. Morris, E. Keramaris, H. J. Rideout, et al., “Cyclin-
dependent kinases and p53 pathways are activated indepen-
dently and mediate Bax activation in neurons after DNA
damage,” Journal of Neuroscience, vol. 21, no. 14, pp. 5017–
5026, 2001.
[37] A. R. Nebreda, “CDK activation by non-cyclin proteins,”
Current Opinion in Cell Biology, vol. 18, no. 2, pp. 192–198,
2006.
[38] T. Hayashi, M. Sakurai, K. Abe, and Y. Itoyama, “DNA
fragmentation precedes aberrant expression of cell cycle-
related protein in rat brain after MCA occlusion,” Neurological
Research, vol. 21, no. 7, pp. 695–698, 1999.
[39] B.-S. Li, L. Zhang, S. Takahashi, et al., “Cyclin-dependent
kinase 5 prevents neuronal apoptosis by negative regulation
of c-Jun N-terminal kinase 3,” The EMBO Journal, vol. 21, no.
3, pp. 324–333, 2002.
[40] J. H. Weishaupt, L. Kussmaul, P. Gr¨ otsch, et al., “Inhibition
of CDK5 is protective in necrotic and apoptotic paradigms of
neuronal cell death and prevents mitochondrial dysfunction,”
Molecular and Cellular Neuroscience, vol. 24, no. 2, pp. 489–
502, 2003.